BACKGROUND: Initial weight loss has been used as a predictor of long-term response to obesity drugs. Discontinuation of drugs has been recommended if weight loss is not ! 1.81 kg (4 lb) in the ®rst month of treatment. OBJECTIVE: We compared the weight loss response at 6 months of patients losing ! 1.81 kg (responders) vs`1.81 kg (non-responders) in the ®rst month of treatment with the combination of fen¯uramine and phentermine. DESIGN: Outcomes at 6 months in 975 patients treated in a comprehensive program of phentermine (15 ± 30 mgad) d,lfen¯uramine (20 ± 60 mgad), were compared for responders vs non-responders. RESULTS: In the total population, ®rst month weight loss highly correlated with % reduction in body mass index (BMI) after 6 months of treatment (P`0.001). The reduction in baseline BMI after 6 months treatment was greater for the responders (15.9% vs 10%, P`0.02). However, the North American Association for the Study of Obesity (NAASO) guidelines for drug treatment of obesity state that a 5% weight loss produces signi®cant health bene®ts, and may be used as a criteria for success. At 6 months, 76%, 37% and 14% of the non-respondents had lost ! 5%, ! 10% and ! 15% of baseline BMI, respectively. After 6 months treatment the reductions in serum cholesterol, triglycerides and LDL-cholesterol were 0.55, 0.31 and 0.42 mmolaL, respectively, (P 0.006), for the non-responders. Adverse effects after 6 months of treatment and the dropout rates after 1 y of treatment were not signi®cantly different for the two groups. CONCLUSIONS: Although, the ®rst month weight loss predicted the long-term response to phen-fen treatment, it was inadequate in identifying the non-responders and may unnecessarily preclude potential bene®ciaries of the treatment.
Introduction
Long term success of the conventional treatment of obesity with diet, exercise and behavior modi®cation is marginal 1 ± 3 and drugs increasingly are being used to treat obesity. Like most other drugs, obesity drugs produce some adverse effects. The possibility of potential adverse effects of an obesity drug warrants screening of potential responders and non-responders to the drug treatment. Drugs could be discontinued for the potential non-responders if they could be identi®ed early during the treatment. This would minimize exposure to the potential adverse effects of obesity drugs for people who are less likely to bene®t from them.
Various predictors of drug induced weight loss have been suggested. The package insert for dexfen¯ura-mine recommended reevaluation and possible discontinuation of the drug for patients losing`1.81 kg (4 lb) in the ®rst month of treatment based on studies done by the manufacturer. The cutoff of a 1.81 kg weight loss in the ®rst month of treatment was used widely by physicians to determine non-responders to phentermine-fen¯uramine combination treatment. This criterion has become the standard for evaluating the response to most obesity drugs. 4 The validity of the 1.81 kg cutoff for identifying the responders to all anti-obesity drugs and combinations of drugs has not been adequately studied. Speci®cally, the ability of the 1.81 kg cutoff criteria to predict longterm weight loss was not validated for phenterminefen¯uramine combination treatment. The current study investigated the association between ®rst month weight loss and the % change in body mass index (BMI) after 6 months of treatment with the combination of phentermine and fen¯uramine. Details of the methods and the enrollment criteria have been previously described. 5 Brie¯y, the treatment consisted of initial subject evaluation (including lab test) followed by instructions to follow a low fat high ®ber diet (about 1200 ± 1400 kcalad), lifestyle modi®cation and mild exercise. In addition, patients were prescribed 15 ± 30 mg of phentermine once daily and 20 mg of fen¯uramine two to three times per day. The patients were seen every two weeks for the duration of the study. Repeat laboratory tests were performed every three months.
Methods

Facilities
Subject population: A total of 1352 patients had entered the drug treatment protocol at least 12 months before starting the data analysis. We have previously shown that in this subject population, the BMI reached a nadir after about 6 months of treatment, and remained essentially stable through one year of treatment. 5 To evaluate the long-term effect of the treatment, data were analyzed only for patients completing at least 6 months of treatment (n 975) and had a 6 month follow-up visit. Due to a small number of men in the sample, the data were not analyzed separately for men and women and the weight loss response was evaluated as change in BMI.
Data management and statistical analysis: Paradox 3.1 (Borland) was used for database management. Comparisons between and within two groups were made using Students t-test, paired t-test, Pearson's correlation, or w 2 distribution, as appropriate.
Results
Out of 1352 subjects, 975 subjects completed 6 months of treatment. Based on the weight loss during the ®rst month of treatment these 975 subjects were divided in two groups: non-responders (weight loss`1.81 kg, n 43) and responders (weight loss ! 1.81 kg, n 932). Mean age of the responders and the non-responders did not differ, but the BMI of the responders was signi®cantly greater (Table 1) . Percent change in BMI after 6 months of treatment was signi®cantly greater for the responders vs the nonresponders ( 7 15.9%AE 0.2 vs 7 10%AE 2.3, P`0.02, Table 1 ). Weight change in the ®rst month for the two groups combined correlated signi®cantly with the % BMI change after 6 months of treatment (r 0.3775, P`0.001).
Although the initial response to the treatment predicted the change in BMI after 6 months of treatment, improvements in serum cholesterol, triglycerides and LDL-cholesterol after 6 months of treatment were similar for the responders and the non-responders. Analysis was conducted only for the subjects with fasting laboratory values available at 0 and 6 months (n 29 non-responders and 563 for responders). The non-responders experienced a signi®cant reduction of (mean AE s.e.) 7 0.55AE 0.13 mmolaL for serum cholesterol, 7 0.41AE 0.11 for LDL-cholesterol, and 7 0.31AE 0.1 mmolaL for serum triglycerides, compared to their baseline levels (P`0.002). Compared to the baseline values, the reductions for serum cholesterol, LDL-cholesterol and serum triglycerides for the responders were 7 0.73 AE 0.03, 7 0.52AE 0.03 and 7 0.41 AE 0.02 mmolaL, respectively, P`0.002). Compared to the baseline, reduction in blood glucose was 7 0.19AE 0.16 mmolaL (P ns) for the nonresponders and 7 0.28AE 0.04 mmolaL (P`0.002) for the responders. Change in HDL-cholesterol from baseline was 0.01AE 0.04 mmolaL (P ns) for the non-responders and 7 0.02AE 0.01 mmolaL (P`0.02) for the responders. However, changes in serum total cholesterol and its fractions, serum triglycerides and blood glucose after 6 months of treatment were not different for the responders vs the non-responders.
About 98% of the responders achieved at least a 5% reduction in their baseline BMI after 6 months of treatment, and 83% and 53% of the responders lost ! 10% and 15% of BMI, respectively. Also, 77% of the non-responders lost at least 5% of the baseline BMI, 37% lost ! 10% and 14% of the subjects lost ! 15% of their baseline BMI. Further analysis of the non-responders showed that as many as 71% of the subjects losing 0.9 kg (2 lb) in the ®rst month and 69% of the subjects losing 0.45 kg (1 lb) in the ®rst month achieved a ! 5% reduction in BMI after 6 months of treatment (Table 2) . Thus, irrespective of the ®rst month weight loss, % of non-responders losing at least 5% of baseline BMI was nearly the same (Table 2) .
After 6 months of treatment, the percentage of subjects reporting various adverse effects were not different for any of the adverse effects reported for the responders vs the non-responders (data not shown). The dropout rate at the end of 12 months of treatment Table 1 A comparison of baseline characteristics of the responders and the non-responders and % change in BMI after 6 months of treatment. Mean AE s.e. was not different for the two groups (responders vs non-responders, 48.2% vs 58.6%, P 0.3). BMI change in the ®rst month of treatment for those who dropped out before completing 6 months of treatment was 7 4.98AE 0.01% vs 7 5.86AE 0.002% (P`0.00001) for the 975 subjects who completed 6 months of treatment. Although the ®rst month response was signi®cantly different for these two groups, a substantial reduction in BMI of nearly 5% in the ®rst month of treatment makes`poor initial response' an unlikely reason for dropping out of the program before completing 6 months of treatment.
Non-responders
Discussion
Most pharmacological agents available for the treatment of obesity have the potential of triggering adverse effects in patients. Therefore, assessing the risk-bene®t ratio for every candidate for drug treatment of obesity is important. Although various predictors of weight loss have been proposed, the search for a satisfactory predictor of weight loss continues. Discontinuing the pharmacotherapy for those who are less likely to respond to weight reducing drugs is a reasonable approach. This requires identi®cation of the`non-responders' early in the treatment. Statements on obesity management published by several organizations suggest that the`non-responders' be identi®ed early in the treatment in order to discontinue drug treatment for these individuals.
4,6 ± 8 A weight loss of`1.81 kg in the ®rst month of treatment is a widely accepted criteria to de®ne`non-responders' to pharmacological treatment of obesity. This criteria is mainly based on the data from the INDEX clinical trial of dexfen¯uramine. 9 The cutoff of 1.81 kg of weight loss in the ®rst month of treatment has also been adapted for obesity treatment with sibutramine. 10 Guidance for treatment of adult obesity' by Shape-up America and the American Obesity Association 4 suggest re-evaluation of the pharmacological treatment of obesity if the ®rst month weight loss is less than 1.81 kg.
There are two main concerns about the use of 1.81 kg weight loss as a criteria to identify thè non-responders'. The ®rst concern is about the use of actual (and not percentage) weight change for de®ning the`non-responders'. It is well known that the weight loss response to a treatment correlates with the baseline weight. Thus, heavier patient are likely to be classi®ed as the`responders'. This was the case in the present study as the initial BMI of the responders was signi®cantly greater than the non-responders ( Table 1) .
The second concern is about the appropriateness of the 1.81 kg cutoff to de®ne non-responders. Many patients would be withdrawn from the drug treatment and be denied potential bene®ts of drug treatment of obesity if the 1.81 kg criteria were too stringent. In this study, the weight loss in the ®rst month did predict the weight loss after 6 months of treatment. There was a correlation between the weight loss in the ®rst month and after 6 months in the whole population and in the two subpopulations. However, the question to be addressed is whether the so-called`non-responders' received any health bene®ts after 6 months of treatment. The guidelines for the treatment of obesity by several expert committees consider a weight loss as little as 5 to 10% as suf®cient to derive health bene®ts from weight loss. 11 Although 98% of our responders lost at least 5% of initial BMI after 6 months of treatment, 77% of the`non-responders' also lost at least 5% of initial BMI and 37% lost 10% or more of initial BMI after 6 months of treatment. Not only was the 1.81 kg cutoff too stringent for this population, but 69% of those losing only 0.45 kg of weight in the ®rst month achieved at least a 5% reduction in BMI after 6 months of treatment (Table 2 ). These`nonresponders' would have been deprived of the potential bene®ts of weight loss had the drug treatment been discontinued for them based on their weight loss in the ®rst month. Additionally, the non-responders had signi®cant reductions in serum cholesterol and triglycerides after 6 months of treatment, and they did not differ from the responders in reported adverse events and a dropout rate even after 1 y of treatment.
These results are obtained from a combination drug treatment of phentermine and fen¯uramine and may not be representative of results with other single agents or combinations. Our data suggest that the widely accepted criteria of`1.81 kg weight loss in the ®rst month to determine the`non-responders' would grossly overestimate the`non-responders' in our population. Therefore, it may not be appropriate to generalize the criteria for identifying non-responders to any obesity drug. We suggest that a more appropriate criteria should be developed to identify thè non-responders' to various obesity drugs. In any case, physicians must take the responsibility to do careful individual assessment of each patient to determine whether or not continued treatment is indicated.
